Chamindi Seneviratne, MD

Riga Stradins University (Medical Academy of Latvia), Riga, Latvia

University of Texas Health Science Center at San Antonio, Texas

University of Virginia, Charlottesville, Va

Addiction genomics, pharmacogenetics, biomarkers, Alcoholism, Substance use disorders, addiction phase-1 trials

Seneviratne C, Gorelick DA, Lynch KG, Brown C, Romer D, Pond T, Kampman K, Kranzler HR. A randomized, double-blind, placebo-controlled, pharmacogenetic study of ondansetron for treating alcohol use disorder. Alcohol Clin Exp Res. 2022 Oct;46(10):1900-1912. doi: 10.1111/acer.14932. Epub 2022 Sep 11. PMID: 36055978; PMCID: PMC9901168.

Cornell J, Conchas A, Wang XQ, Fink JC, Chen H, Kane MA, Pilli N, Ait-Daoud N, Gorelick DA, Li MD, Johnson BA, Seneviratne C. Validation of serotonin transporter mRNA as a quantitative biomarker of heavy drinking and its comparison to ethyl glucuronide/ethyl sulfate: A randomized, double-blind, crossover trial. Alcohol Clin Exp Res. 2022 Oct;46(10):1888-1899. doi: 10.1111/acer.14931. Epub 2022 Sep 11. PMID: 36031718; PMCID: PMC9588643.

Seneviratne C, Noel J, Franklin PD, Colloca L. Editorial: Harnessing placebo mechanisms. Front Psychiatry. 2022 Sep 12;13:1022762. doi: 10.3389/fpsyt.2022.1022762. PMID: 36172509; PMCID: PMC9512394.

Seneviratne C and Johnson B.A. Advances in Medications and Tailoring Treatment for Alcohol Use Disorder. Alcohol Res. 2015; 37(1): 15–28.

Yang Z^*, Seneviratne C^*, Wang S, Ma JZ, Payne TJ, Wang J, Li MD. Serotonin transporter and receptor genes significantly impact nicotine dependence through genetic interactions in both European American and African American smokers. Drug Alcohol Depend. 2013 May 1; 129(3):217-25. (^*Authors contributed equally)